SCL 340B Care is happy to share insights, news, and comments relevant to the 340B program to help you stay informed. Learn about current legislation, technology solutions, administrative challenges, and more that impact the program, safety net providers, drug manufacturers, and the health of Americans. Senate...

Medicare patients could save an estimated $150 million on out-of-pocket co-payments for clinic visits if proposed changes to the hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Cancer (ASC) payment system are supported by the Centers for Medicare & Medicaid Services (CMS) for 2019. The...

In 2015, the 340B Drug Discount Program saved healthcare providers $6 billion on drug acquisition costs. While the program aims to make pharmaceutical and clinical care affordable and accessible to low-income patients; there is evidence that some participating entities are exploiting its discounts for profit. Since close...

A recent report from the National Academies of Sciences, Engineering, and Medicine shows that the need for effective and affordable medicines is being underserved by the biopharmaceutical sector. The report is composed of eight (8) recommendations and twenty-seven (27) strategies aimed to improve prescription drug...

The 340B Drug Pricing Program "mega-guidance" spends its third month at the OMB. It is suspected that contract pharmacy arrangements will see some revisions which will reduce duplicate discounts paid by manufacturers. In the past, HRSA planned to issue a "mega-reg" that would address contract pharmacy arrangements...

Our healthcare industry is evolving into a fee-for-value payment system, which promotes value and efficiency. This new system increases the quality of care and focuses on the outcome of treatment for its patients. This industry improvement is now encountering astronomical price increases of prescription drugs...